Care Rail

← Medical · Causes of death · how systems treat it

Parkinson disease

Neurologic · Master rank #21 · ~1.5% of deaths (Top 20 avg)

Short comparison of all 20 systems on one page. Click a country for the full treatment / prevention / lifestyle page.

Illustrative playbooks — composed from system archetype + cause pathway. Not clinical guidelines.
United Kingdom#19 · 1.5%
NHS tax-funded

GP gatekeeping, NICE pathways, waiting-list rationing for elective care. Neurologic pathway via NHS tax-funded.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Spain#19 · 1.5%
SNS tax-funded

Strong primary care; Mediterranean public-health framing. Neurologic pathway via SNS tax-funded.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Israel#19 · 1.5%
Mandatory health funds

Fund-integrated care; strong tech/trauma capacity. Neurologic pathway via Mandatory health funds.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Italy#19 · 1.5%
SSN tax-funded

GP gatekeeping; north/south performance gaps. Neurologic pathway via SSN tax-funded.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Netherlands#20 · 1.5%
Mandatory private insurance, regulated

Insurer-organized pathways; low uninsured rate. Neurologic pathway via Mandatory private insurance, regulated.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Singapore#20 · 1.5%
S+3Ms (subsidy + MediSave + MediShield + MediFund)

Public clusters for most serious care; private ISP for those who pay up. Neurologic pathway via S+3Ms (subsidy + MediSave + MediShield + MediFund).

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Sweden#20 · 1.5%
Decentralized tax-funded

Primary-care centered; strong public health infrastructure. Neurologic pathway via Decentralized tax-funded.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Norway#20 · 1.5%
Tax-funded national system

Wealthy Nordic model; GP lists + municipal prevention. Neurologic pathway via Tax-funded national system.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
France#20 · 1.5%
Statutory health insurance

Ambulatory specialist access; strong pharma/device availability. Neurologic pathway via Statutory health insurance.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Switzerland#20 · 1.6%
Mandatory private insurance

High spend, high access, canton variation. Neurologic pathway via Mandatory private insurance.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Denmark#20 · 1.5%
Tax-funded

Municipal prevention + regional hospitals. Neurologic pathway via Tax-funded.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Canada#20 · 1.5%
Single payer (provincial)

Single-payer core with wait times; limited private parallel. Neurologic pathway via Single payer (provincial).

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Germany#20 · 1.5%
Statutory sickness funds

Ambulatory specialists + hospital sector; dense capacity. Neurologic pathway via Statutory sickness funds.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Finland#20 · 1.4%
Tax-funded / reforming

Public primary care + occupational health overlay. Neurologic pathway via Tax-funded / reforming.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Australia#21 · 1.5%
Universal Medicare + private optional

Strong primary care gatekeeping with private hospital overflow. Neurologic pathway via Universal Medicare + private optional.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Japan#21 · 1.5%
Statutory insurance, fee schedule

High visit frequency, low unit prices, specialist access without US-style referral walls. Neurologic pathway via Statutory insurance, fee schedule.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
South Korea#21 · 1.5%
NHI single payer + private hospitals

Very high utilization; hospital-heavy; aggressive screening culture. Neurologic pathway via NHI single payer + private hospitals.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
New Zealand#21 · 1.5%
Tax-funded + private optional

Pharmac constrains drug spend; public hospitals for major care. Neurologic pathway via Tax-funded + private optional.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
Taiwan#21 · 1.5%
NHI single payer

High ambulatory volume; global budgets constrain growth. Neurologic pathway via NHI single payer.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →
United States#22 · 1.4%
Medicare/Medicaid + commercial

High-tech acute care; prior auth; huge price variation by payer. Neurologic pathway via Medicare/Medicaid + commercial.

Treat Symptomatic drugs (cholinesterase inhibitors, levodopa, etc.)
Prevent Vascular risk-factor control (for vascular dementia / stroke sequelae)
Lifestyle Cognitive / social activity; Mediterranean-style diet patterns
Full page →